


Application No. 10/645,312
 Amendment dated October 4, 2005
 Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

AMENDMENTS TO THE CLAIMS**Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A compound of the Formula:



or a pharmaceutically acceptable salt thereof, wherein:

G is oxygen or NH;

Rx is straight or branched chain C₁₋₈alkyl;

R₁ and R₃ are independently selected from hydrogen, cyano, C₁₋₄alkyl, halogen, C₁₋₂haloalkyl, C₁₋₂haloalkoxy, mono- and di-C₁₋₄alkylamino, C₁₋₄alkoxy, and C₁₋₄alkylthio;

R₅ is hydrogen, halogen, hydroxymethyl, hydroxy, C₁₋₄alkyl, or C₁₋₄alkoxy;

K is N or CR₆ where R₆ is hydrogen, halogen, cyano, C₁₋₂alkyl, or C₁₋₂alkoxy;

R₇ is halogen, hydrogen, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₂haloalkyl, C₁₋₂haloalkoxy, mono- and di-C₁₋₄alkylamino, mono- and di-(C₁₋₂alkyl)aminoC₁₋₄alkyl, C₁₋₂alkoxyC₁₋₄alkyl, C₁₋₂alkoxycarbonyl, mono- and di-C₁₋₂alkylcarboxamido, -C(=O)NH₂, hydroxyC₁₋₂alkyl, trifluoromethylsulfonyl, 2,2,2-trifluoroethanol, or a 4-7 member heterocycloalkyl group containing 1 or 2 atoms independently chosen from N, O, and S;

R₈ is hydrogen, halogen, hydroxy, C₁₋₂alkyl, C₁₋₂alkoxy, or mono- and di-(C₁₋₂alkyl)amino, and J is N or CR₉ where R₉ is hydrogen, halogen or C₁₋₂alkyl;

2. (Original) A compound or salt according to Claim 1 wherein R₁ and R₃ are not hydrogen.

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

3. (Canceled).

4. (Canceled).

5. (Original) A compound or salt according to Claim 1 wherein G is NH and R_X is 1-ethyl propyl.

6. (Original) A compound or salt according to Claim 5 wherein R₁ is cyano, methoxy, or methylthio and R₃ is methyl or ethyl.

7. (Original) A compound or salt according to Claim 1 wherein G is oxygen and R_X is 1-ethylpropyl, 1-isopropyl-2-methypropyl, 1-propylbutyl, or 1-ethylbutyl.

8. (Original) A compound or salt according to Claim 7 wherein R₃ is halogen, C₁₋₂alkyl, or methylamino.

9. (Original) A compound or salt according to Claim 7 wherein R₁ is halogen, methyl, methoxy, ethyl, ethoxy, or C₁₋₂alkylamino.

10. (Original) A compound or salt according to Claim 7 wherein R₁ is methylamino.

11. (Currently amended) A compound selected from
~~5-ethyl-6-(1-ethylpropoxy)-3-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;~~
~~5-bromo-3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;~~
~~3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,N-dimethylpyrazin-2-amine;~~
~~2-(4-tert-butyl-2-methoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)pyrazine;~~
~~2-(4-tert-butyl-2-methoxyphenyl)-3,6-diethyl-5-(1-isopropyl-2-methylpropoxy)pyrazine;~~
~~2,5-diethyl-3-(1-ethylpropoxy)-6-(4-isopropyl-2-methoxyphenyl)pyrazine;~~

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

2,5-diethyl-3-(4-isopropyl-2-methoxyphenyl)-6-(1-isopropyl-2-methylpropoxy)pyrazine;
2-(2,6-dimethoxypyridin-3-yl)-3,6-diethyl-5-(1-ethylpropoxy)pyrazine;
2-(2,6-dimethoxypyridin-3-yl)-3,6-diethyl-5-(1-isopropyl-2-methylpropoxy)pyrazine;
2,5-diethyl-3-(4-ethyl-2-methoxyphenyl)-6-(1-ethylpropoxy)pyrazine;
2-[2-chloro-4-(difluoromethoxy)phenyl]-3,6-diethyl-5-(1-propylbutoxy)pyrazine;
2,5-diethyl-3-(1-ethylpropoxy)-6-(4-isopropyl-2-methoxyphenyl)pyrazine;
2,5-diethyl-3-(1-ethylpropoxy)-6-(2-fluoro-4,6-dimethoxyphenyl)pyrazine; and
2,5-diethyl-3-(2-fluoro-4,6-dimethoxyphenyl)-6-(1-isopropyl-2-methylpropoxy)pyrazine;
2,5-diethyl-3-(4-isopropyl-2-methoxyphenyl)-6-(1-propylbutoxy)pyrazine;
5-(1-ethylpropoxy)-3-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-methylpyrazine;
2-chloro-3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-5-methylpyrazine;
2-(1-ethylpropoxy)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrazine;
6-[4-(difluoromethoxy)-2-methoxyphenyl]-3-(1-ethylpropoxy)-N,5-dimethylpyrazin-2-amine;
5-[3,6-diethyl-5-(1-isopropyl-2-methylpropoxy)pyrazin-2-yl]-6-methoxy-N,N-dimethylpyridin-2-amine;
5-bromo-6-[4-(difluoromethoxy)-2-methoxyphenyl]-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
2-chloro-3-(1-ethylpropoxy)-6-(4-isopropyl-2-methoxyphenyl)-5-methylpyrazine;
3-(1-ethylpropoxy)-6-(4-isopropyl-2-methoxyphenyl)-N,5-dimethylpyrazin-2-amine;
5-(1-ethylpropoxy)-2-[2-methoxy-4-(trifluoromethyl)phenyl]-3-methylpyrazine;
5-bromo-3-(1-ethylbutoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;
2-chloro-3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-5-methylpyrazine;
3-(1-ethylbutoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethylpyrazin-2-amine;
3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N,5-dimethylpyrazin-2-amine; and
5-bromo-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
5-bromo-6-[4-(difluoromethoxy)-2-methoxyphenyl]-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine;
6-[4-(difluoromethoxy)-2-methoxyphenyl]-3-(1-ethylbutoxy)-N,5-dimethylpyrazin-2-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

5-bromo-6-(5-bromo-4-ethoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
6-(4-ethoxy-2-methoxy-5-methylphenyl)-3-(1-ethylpropoxy)-N,N-dimethylpyrazin-2-amine;
5-bromo-6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine;
5-bromo-6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
5-bromo-3-ethoxy-6-(4-ethoxy-2-methoxyphenyl)-N-methylpyrazin-2-amine;
6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylbutoxy)-N,N-dimethylpyrazin-2-amine;
6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N,N-dimethylpyrazin-2-amine;
5-bromo-6-(4-ethoxy-2-methoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
5-bromo-3-(1-ethylbutoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N-methylpyrazin-2-amine;
6-(4-ethoxy-2-methoxyphenyl)-N,N-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
5-bromo-6-(5-bromo-4-ethoxy-2-methoxyphenyl)-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine;
6-(5-bromo-4-ethoxy-2-methoxyphenyl)-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine;
6-(4-ethoxy-2-methoxy-5-methylphenyl)-3-(1-ethylbutoxy)-N,N-dimethylpyrazin-2-amine;
5-bromo-3-(1-ethylbutoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N-methylpyrazin-2-amine;
5-bromo-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
3-(1-ethylbutoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N,N-dimethylpyrazin-2-amine;
6-[2-methoxy-4-(trifluoromethyl)phenyl]-N,N-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
5-bromo-3-(1-ethylpropoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N-methylpyrazin-2-amine;
3-(1-ethylpropoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N,N-dimethylpyrazin-2-amine;
3-(1-ethylpropoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)-N,N-dimethylpyrazin-2-amine;
5-ethyl-3-(1-ethylpropoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)-N-methylpyrazin-2-amine;
3-(1-ethylbutoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N,N-dimethylpyrazin-2-amine;
6-(2-ethyl-4-methoxyphenyl)-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-carbonitrile;
6-(2,4-dimethoxyphenyl)-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-carbonitrile;
5-[6-(dimethylamino)-2-ethylpyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

6-[2-chloro-4-(trifluoromethyl)phenyl]-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-carbonitrile;
6-(2,6-dimethoxyptidin-3-yl)-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-carbonitrile;
3-[(1-ethylpropyl)amino]-6-mesityl-5-methylpyrazine-2-carbonitrile;
6-(4-chloro-2,6-dimethoxyphenyl)-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-carbonitrile;
3-[(1-ethylpropyl)amino]-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-5-methylpyrazine-2-carbonitrile;
5-[2-chloro-4-(trifluoromethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
5-[6-(dimethylamino)-2-ethylpyridin-3-yl]-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine;
5-[6-(dimethylamino)-2-ethylpyridin-3-yl]-N-(1-ethylpropyl)-6-methyl-3-(methylthio)pyrazin-2-amine;
5-bromo-6-(2-chloro-4-isopropoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
5-bromo-6-(2-chloro-4-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
6-(2-chloro-4-methoxyphenyl)-3-(1-ethylpropoxy)-N,5-dimethylpyrazin-2-amine;
6-(2-chloro-4-isopropoxyphenyl)-3-(1-ethylpropoxy)-N,5-dimethylpyrazin-2-amine;
N-(1-ethylpropyl)-5-mesityl-3-methoxy-6-methylpyrazin-2-amine;
5-[6-(dimethylamino)-2,4-dimethylpyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
3-(1-ethylpropoxy)-6-(4-isopropoxy-2-methylphenyl)-N,5-dimethylpyrazin-2-amine;
5-bromo-3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N-methylpyrazin-2-amine;
N-(1-ethylpropyl)-5-(6-isopropyl-2-methoxypyridin-3-yl)-3-methoxypyrazin-2-amine;
5-bromo-3-(1-ethylpropoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)-N-methylpyrazin-2-amine;
5-bromo-6-(2-chloro-4-methoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
6-(2-chloro-4-methoxyphenyl)-5-ethyl-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
5-bromo-6-(2-chloro-4-methoxyphenyl)-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine;
6-(2-chloro-4-methoxyphenyl)-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
2,5-diethyl-3-(1-ethylpropoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)pyrazine;
3-[(+/-)-1-ethylbutyl]oxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethylpyrazin-2-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

~~3-[(1S)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;~~
~~5-bromo-3-[(1S)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;~~
~~3-[(1R)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethylpyrazin-2-amine;~~
~~3-[(1R)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;~~
~~5-bromo-3-[(1R)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;~~
~~5-(2,4-dimethoxypyrimidin-5-yl)-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;~~
~~5-(2,4-dimethoxypyrimidin-5-yl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine;~~
~~N-(1-ethylpropyl)-5-(6-isopropyl-2-methoxypyridin-3-yl)-6-methyl-3-(methylthio)pyrazin-2-amine;~~
~~6-(2-chloro-4-methoxyphenyl)-3-(1-ethylbutoxy)-N,S-dimethylpyrazin-2-amine;~~
~~3-(1-ethylbutoxy)-6-(4-methoxy-2-methylphenyl)-N,S-dimethylpyrazin-2-amine;~~
~~5-bromo-6-(2-chloro-4-ethoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;~~
~~5-bromo-6-(2-chloro-4-ethoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;~~
~~2,5-diethyl-3-(1-ethylbutoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)pyrazine;~~
~~5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;~~
~~5-[6-(dimethylamino)-2-methoxypyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;~~
~~N-(1-ethylpropyl)-3,6-dimethoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]pyrazin-2-amine;~~
~~methyl-4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl]-3,5-dimethoxybenzoate;~~
~~4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl]-3,5-dimethoxy-N-methylbenzamide;~~
~~5-bromo-6-(4-isopropoxy-2-methoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;~~
~~3-(1-ethylpropoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N-methylpyrazin-2-amine;~~
~~6-ethyl-N-(1-ethylpropyl)-5-(4-isopropyl-2,6-dimethoxyphenyl)-3-methoxypyrazin-2-amine;~~

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

N-(1-ethylpropyl)-5-(4-isopropyl-2,6-dimethoxyphenyl)-6-methyl-3-(methylthio)pyrazin-2-amine;
5-[4-(dimethylamino)methyl]-2,6-dimethoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
+-(4-[5-(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl)-3,5-dimethoxyphenyl)-2,2,2-trifluoroethanol;
5-(2,6-dimethoxypyridin-3-yl)-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
5-(2,6-dimethoxypyridin-3-yl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine;
4-[5-(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl]-3,5-dimethoxybenzamide;
2-[5-(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl]-5-(trifluoromethoxy)phenol;
6-(4-isopropoxy-2-methoxyphenyl)-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
4-[5-(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl]-3,5-dimethoxy-N,N-dimethylbenzamide;
4-[5-(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl]-N,3,5-trimethoxy-N-methylbenzamide;
5-bromo-6-(5-bromo-4-isopropoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
2,5-diethyl-3-(1-ethylpropoxy)-6-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]pyrazine;
N-(1-ethylpropyl)-5-(6-isopropyl-4-methoxypyridin-3-yl)-3-methoxy-6-methylpyrazin-2-amine;
5-(2-chloro-6-isopropylpyridin-3-yl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine;
5-bromo-3-(1-ethylbutoxy)-6-(4-isopropyl-2-methoxyphenyl)-N-methylpyrazin-2-amine;
5-bromo-3-(1-ethylpropoxy)-6-(4-isopropyl-2-methoxyphenyl)-N-methylpyrazin-2-amine;
5-bromo-6-(4-isopropyl-2-methoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
3-ethoxy-6-(4-isopropyl-2-methoxyphenyl)-N,5-dimethylpyrazin-2-amine;
6-(4-isopropyl-2-methoxyphenyl)-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
3-(1-ethylbutoxy)-6-(4-isopropyl-2-methoxyphenyl)-N,5-dimethylpyrazin-2-amine;
N³-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrazine-2,3-diamine;
N²-(1-ethylpropyl)-5-(4-isopropyl-2-methoxyphenyl)-6-methylpyrazine-2,3-diamine;
5-bromo-N³-(1-ethylpropyl)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N²-methylpyrazine-2,3-diamine;
5-(4-chloro-2,6-dimethoxyphenyl)-N²-(1-ethylpropyl)-6-methylpyrazine-2,3-diamine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

N²-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-N³,N³,6-trimethylpyrazine-2,3-diamine;
N²-(1-ethylpropyl)-5-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]-6-methylpyrazine-2,3-diamine;
5-ethyl-N³-(1-ethylpropyl)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N³-methylpyrazine-2,3-diamine;
N-(1-ethylpropyl)-5-(4-isopropyl-2,6-dimethoxyphenyl)-3-methoxy-6-methylpyrazin-2-amine;
N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]-6-methylpyrazin-2-amine;
6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-amine;
N-(1-ethylpropyl)-5-[4-(1-fluoro-1-methylethyl)-2,6-dimethoxyphenyl]-3-methoxy-6-methylpyrazin-2-amine;
16-N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrazin-2-amine;
N-(1-ethylpropyl)-5-(6-isopropyl-2-methoxypyridin-3-yl)-3-methoxy-6-methylpyrazin-2-amine;
6-ethyl-N-(1-ethylpropyl)-5-(6-isopropyl-2-methoxypyridin-3-yl)-3-methoxypyrazin-2-amine;
6-ethyl-N-(1-ethylpropyl)-5-(4-isopropyl-2-methoxyphenyl)-3-methoxypyrazin-2-amine;
N-(1-ethylpropyl)-5-(4-isopropyl-2-methoxyphenyl)-3-methoxy-6-methylpyrazin-2-amine;
N-(1-ethylpropyl)-3-methoxy-5-(2-methoxy-6-pyrrolidin-1-ylpyridin-3-yl)-6-methylpyrazin-2-amine;
5-[2,6-dimethoxy-4-(1,2,2,2-tetrafluoroethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-(2-methoxy-6-pyrrolidin-1-ylpyridin-3-yl)pyrazin-2-amine;
(4-[5-(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl)-3,5-dimethoxyphenylmethanol;
5-[6-(dimethylamino)-2-methylpyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
5-[2,6-dimethoxy-4-(1-methoxyethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

5-[4-(1-ethoxyethyl)2,6-dimethoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
5-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
4-[5-(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl]-3-methoxyphenyl trifluoromethanesulfonate;
1-[5-(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl]-3-methoxybenzonitrile;
4-[5-(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl]-3,5-dimethoxybenzaldehyde-O-methyloxime;
N-(1-ethylpropyl)-5-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]-6-methyl-3-(methylthio)pyrazin-2-amine;
5-(4-chloro-2,6-dimethoxyphenyl)-N-(1-ethylpropyl)-6-methyl-3-(methylthio)pyrazin-2-amine;
N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methyl-3-(methylthio)pyrazin-2-amine;
5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-6-methyl-3-(methylthio)pyrazin-2-amine;
N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-6-methyl-3-(methylthio)pyrazin-2-amine;
5-[2-chloro-4-(trifluoromethyl)phenyl]-N-(1-ethylpropyl)-6-methyl-3-(methylthio)pyrazin-2-amine; and
N-(1-ethylpropyl)-5-mesityl-6-methyl-3-(methylthio)pyrazin-2-amine, or a pharmaceutically acceptable salt thereof.

12. (Original) A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits a K_i value for CRF receptors of less than or equal to 1 micromolar.

13. (Original) A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits a K_i value for CRF receptors of less than or equal to 100 nanomolar.

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

14. (Original) A compound or salt according to Claims 1 wherein, in a standard in vitro CRF receptor binding assay, the compound exhibits a K_i value for CRF receptors of less than or equal to 10 nanomolar.

15. (Withdrawn) A method for treating anxiety, depression, or stress comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt according to Claim 1.

16. (Withdrawn) A method for treating irritable bowel syndrome or Crohn's disease, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt according to Claim 1.

17. (Withdrawn) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound or salt of Claim 1.

18. (Withdrawn) A pharmaceutical composition according to Claim 17, wherein the composition is formulated as an injectable fluid, an aerosol, a cream, a gel, a tablet, a pill, a capsule, a syrup or a transdermal patch.

19. (Withdrawn) A package comprising a pharmaceutical composition of Claim 17 in a container and further comprising indicia comprising at least one of:

instructions for using the composition to treat a patient suffering from anxiety, or
instructions for using the composition to treat a patient suffering from stress, or
instructions for using the composition to treat a patient suffering from depression.

20. (Withdrawn) A package comprising a pharmaceutical composition of Claim 17 in a container and further comprising at least one of: instructions for using the composition to treat a patient suffering from irritable bowel syndrome or instructions for using the composition to treat a patient suffering from Crohn's disease.

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

21. (Withdrawn) A method for demonstrating the presence or absence of CRF 1 receptors in a biological sample, said method comprising:

- a) contacting the biological sample with a labeled compound according to Claim 1 under conditions that permit binding of the labeled compound to a CRF1 receptor;
- b) separating unbound labeled compound from bound labeled compound; and
- c) detecting the bound labeled compound in the biological sample, and therefrom determining the presence or absence of CRF1 receptors in the sample.

22. (Withdrawn) The method of Claim 21 wherein the labeled compound is detected using autoradiography.

23. (Withdrawn) A method of inhibiting the binding of CRF to a CRF1 Receptor, which method comprises:

contacting a solution comprising CRF and a compound or salt of Claim 1 with a cell expressing the CRF receptor, wherein the compound or salt is present in the solution at a concentration sufficient to inhibit *in vitro* CRF binding to IMR32 cells.

24. (Withdrawn) The method of Claim 23 wherein the cell expressing the CRF receptor is a neuronal cell that is contacted *in vivo* in an animal, and wherein the solution is a body fluid of said animal.

25. (Withdrawn) The method of Claim 23 wherein the animal is a human patient.

26. (Previously presented) A compound selected from:

- [6-(6-Dimethylamino-4-ethyl-2-methyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;
- [6-(6-Dimethylamino-4-ethyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;
- [6-(6-Dimethylamino-2,4-dimethyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;
- [5-Ethyl-6-[2-(ethyl-methyl-amino)-6-isopropyl-pyridin-3-yl]-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

2-(*{3-[3-Ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-6-isopropyl-pyridin-2-yl}-methyl-amino*)-ethanol;

[5-Ethyl-3-(1-ethyl-propoxy)-6-(6-isopropyl-2-morpholin-4-yl-pyridin-3-yl)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-3-(1-ethyl-propoxy)-6-(6-isopropyl-2-pyrrolidin-1-yl-pyridin-3-yl)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-3-(1-ethyl-propoxy)-6-[6-isopropyl-2-(2-methoxy-ethylamino)-pyridin-3-yl]-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-6-(5-ethyl-6-isopropylamino-2-methyl-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-3-(1-ethyl-propoxy)-6-(6-isopropyl-2-methylamino-pyridin-3-yl)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-6-(2-ethylamino-6-isopropyl-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-3-(1-ethyl-propoxy)-6-(6-isopropyl-2-isopropylamino-pyridin-3-yl)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-3-(1-ethyl-propoxy)-6-(6'-isopropyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3-yl)-pyrazin-2-yl]-methyl-amine;

3-{3-[3-Ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-6-isopropyl-pyridin-2-ylamino}-propan-1-ol;

[6-(2-Azetidin-1-yl-5-bromo-6-isopropyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[6-(2-Azetidin-1-yl-5-ethyl-6-isopropyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-3-(1-ethyl-propoxy)-6-[6-isopropyl-2-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-pyrazin-2-yl]-methyl-amine;

(1-Ethyl-propyl)-[3-methoxy-6-methyl-5-(2,3,4-trimethoxy-phenyl)-pyrazin-2-yl]-amine;

[6-(6-Dimethylamino-4-methoxy-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

Trifluoro-methanesulfonic acid 5-[3-ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-6-methyl-pyridin-2-yl ester;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

[6-(5-Bromo-6-dimethylamino-4-methoxy-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;
[5-Ethyl-6-(5-ethyl-6-isopropyl-2-pyrrolidin-1-yl-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;
2-(4-{3-[3-Ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-6-isopropyl-pyridin-2-yl}-piperazin-1-yl)-ethanol;
N1-{3-[3-Ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-6-isopropyl-pyridin-2-yl}-N1-methyl-ethane-1,2-diamine;
2-{3-[3-Ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-6-isopropyl-pyridin-2-yloxy}-acetamide;
2-{3-[3-Ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-6-isopropyl-pyridin-2-yloxy}-ethanol;
[5-Ethyl-3-(1-ethyl-propoxy)-6-(6-isopropyl-2-piperazin-1-yl-pyridin-3-yl)-pyrazin-2-yl]-methyl-amine;
[5-Ethyl-3-(1-ethyl-propoxy)-6-(2-methyl-6-morpholin-4-yl-pyridin-3-yl)-pyrazin-2-yl]-methyl-amine;
5-[3-Ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-6-methyl-pyridine-2-carbonitrile;
[6-(6-Dimethylamino-4-methoxy-pyridin-3-yl)-3-(1-ethyl-propoxy)-5-methyl-pyrazin-2-yl]-methyl-amine;
[5-Ethyl-6-(5-ethyl-2-methyl-6-morpholin-4-yl-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;
[6-(5-Bromo-6-dimethylamino-2-methyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;
[6-(6-Dimethylamino-4-methoxy-5-methyl-pyridin-3-yl)-3-(1-ethyl-propoxy)-5-methyl-pyrazin-2-yl]-methyl-amine;
[3-Bromo-5-(6-dimethylamino-4-methoxy-pyridin-3-yl)-6-methoxy-pyrazin-2-yl]-{(1-ethyl-propyl)-amine};
{5-[3,6-Diethyl-5-(1-ethyl-propoxy)-pyrazin-2-yl]-4-methoxy-pyridin-2-yl}-dimethyl-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

[5-(6-Dimethylamino-4-methoxy-pyridin-3-yl)-3,6-diethyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-methoxy-pyridin-3-yl)-3-ethyl-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

{5-[3,6-Diethyl-5-(1-ethyl-propoxy)-pyrazin-2-yl]-4-isopropoxy-pyridin-2-yl}-dimethyl-amine;

[5-(6-Dimethylamino-4-isopropoxy-pyridin-3-yl)-3,6-diethyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-isopropoxy-pyridin-3-yl)-3-ethyl-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3-Bromo-5-(6-dimethylamino-4-isopropoxy-pyridin-3-yl)-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-propoxy-pyridin-3-yl)-3,6-diethyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(4-Cyclopentyloxy-6-dimethylamino-pyridin-3-yl)-3,6-diethyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-ethoxy-pyridin-3-yl)-3,6-diethyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-trifluoromethyl-pyridin-3-yl)-3,6-diethyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-ethyl-pyridin-3-yl)-3-ethyl-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-ethyl-pyridin-3-yl)-3,6-diethyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-trifluoromethyl-pyridin-3-yl)-3-ethyl-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Diethylamino-4-methoxy-pyridin-3-yl)-3,6-diethyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

{3,6-Diethyl-5-[6-(ethyl-methyl-amino)-4-methoxy-pyridin-3-yl]-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

[3,6-Diethyl-5-(4-methoxy-6-methylamino-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3,6-Diethyl-5-(6-ethylamino-4-methoxy-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3,6-Diethyl-5-(6-isopropylamino-4-methoxy-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3-Ethyl-5-(4-ethyl-6-ethylamino-pyridin-3-yl)-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

{5-[6-(Ethyl-methyl-amino)-4-methoxy-pyridin-3-yl]-3-methoxy-6-methyl-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-isopropoxy-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-methoxy-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

{3-Ethyl-5-[4-ethyl-6-(ethyl-methyl-amino)-pyridin-3-yl]-6-methoxy-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

[5-(6-Diethylamino-4-ethyl-pyridin-3-yl)-3-ethyl-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Ethylamino-4-methoxy-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(4-Ethyl-6-ethylamino-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Diethylamino-4-ethyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

{5-[4-Ethyl-6-(ethyl-methyl-amino)-pyridin-3-yl]-3-methoxy-6-methyl-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

[5-(4-Ethyl-6-isopropylamino-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Dimethylamino-4-ethyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

[3,6-Diethyl-5-(4-ethyl-6-isopropylamino-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine; and

{5-[4-Ethyl-6-(ethyl-propyl-amino)-pyridin-3-yl]-3-methoxy-6-methyl-pyrazin-2-yl}-(1-ethyl-propyl)-amine.

[5-(6-Dimethylamino-4-ethyl-5-methyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

6,6'-Diethyl-N5,N5'-bis-(1-ethyl-propyl)-3,3'-dimethoxy-[2,2']bipyrazinyl-5,5'-diamine;

{3,6-Diethyl-5-[4-ethyl-6-(ethyl-methyl-amino)-pyridin-3-yl]-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

[5-(6-tert-Butylamino-4-ethyl-pyridin-3-yl)-3-ethyl-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3-Ethyl-5-(4-ethyl-6-isopropylamino-pyridin-3-yl)-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

{5-[4-Ethyl-6-(isopropyl-methyl-amino)-pyridin-3-yl]-3-methoxy-6-methyl-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

[5-(6-tert-Butylamino-4-ethyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(4-Ethyl-6-isobutylamino-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3-Ethyl-5-(6-isopropyl-4-methoxy-pyridin-3-yl)-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

{5-[4-Ethyl-6-(1-ethyl-propylamino)-pyridin-3-yl]-3-methoxy-6-methyl-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

{5-[4-Ethyl-6-(isobutyl-methyl-amino)-pyridin-3-yl]-3-methoxy-6-methyl-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

{6-Ethyl-5-[4-ethyl-6-(isopropyl-methyl-amino)-pyridin-3-yl]-3-methoxy-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

[5-(2-Chloro-4-trifluoromethyl-phenyl)-3,6-diethyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

N2-(1-Ethyl-propyl)-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-6-methyl-pyrazine-2,3-diamine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

1-[4-[3-Ethyl-5-(1-ethyl-propoxy)-6-methylamino-pyrazin-2-yl]-2,5-dimethoxy-phenyl]-ethanone;
[3-(2-Chloro-4-methoxy-phenyl)-5-ethyl-6-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;
[3-(6-Dimethylamino-4-methoxy-pyridin-3-yl)-5-ethyl-6-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;
[5-(6-Dimethylamino-2-ethyl-pyridin-3-yl)-3-ethyl-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;
[3-Bromo-5-(6-dimethylamino-5-methoxymethyl-2-methyl-pyridin-3-yl)-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;
[5-(6-Dimethylamino-5-methoxymethyl-2-methyl-pyridin-3-yl)-3-ethyl-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;
[3,6-Diethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine;
1-[3-[3,6-Diethyl-5-(1-ethyl-propylamino)-pyrazin-2-yl]-6-isopropyl-pyridin-2-ylamino]-propan-2-ol;
3-[3-[3,6-Diethyl-5-(1-ethyl-propylamino)-pyrazin-2-yl]-6-isopropyl-pyridin-2-ylamino]-propan-1-ol;
2-[3-[3,6-Diethyl-5-(1-ethyl-propylamino)-pyrazin-2-yl]-6-isopropyl-pyridin-2-ylamino]-ethanol;
[3-Ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;
1-{2-Dimethylamino-5-[6-ethyl-5-(1-ethyl-propylamino)-3-methoxy-pyrazin-2-yl]-6-methyl-pyridin-3-yl}-ethanol;
1-[4-Ethyl-5-[6-ethyl-5-(1-ethyl-propylamino)-3-methoxy-pyrazin-2-yl]-2-methoxy-phenyl]-ethanol;
[3,6-Diethyl-5-(6-isopropyl-2-methylamino-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine;
(1-Ethyl-propyl)-[5-(2-methoxy-4-trifluoromethoxy-phenyl)-6-methyl-pyrazin-2-yl]-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

[3-Bromo-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[6-Chloro-3-ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3,6-Diethyl-5-(6-ethyl-2-methoxy-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[6-Chloro-3-ethyl-5-(6-isopropyl-2-methylamino-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3,6-Diethyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3-Ethyl-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3-Ethyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(2-Ethyl-6-isopropyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

2-[3-[5-(1-Ethyl-propylamino)-6-methoxy-3-methyl-pyrazin-2-yl]-6-isopropyl-pyridin-2-ylamino]-ethanol;

3-[3-[5-(1-Ethyl-propylamino)-6-methoxy-3-methyl-pyrazin-2-yl]-6-isopropyl-pyridin-2-ylamino]-propan-1-ol;

(1-Ethyl-propyl)-[5-(6-isopropyl-2-morpholin-4-yl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-amine;

(1-Ethyl-propyl)-{5-[6-isopropyl-2-(2-methoxy-ethylamino)-pyridin-3-yl]-3-methoxy-6-methyl-pyrazin-2-yl}-amine;

(1-Ethyl-propyl)-{5-[6-isopropyl-2-(3-morpholin-4-yl-propylamino)-pyridin-3-yl]-3-methoxy-6-methyl-pyrazin-2-yl}-amine;

(1-Ethyl-propyl)-[5-(6-isopropyl-2-methylamino-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-amine;

[3-Ethoxy-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3-Ethyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

[3-Bromo-5-(6-dimethylamino-4-ethyl-pyridin-3-yl)-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

{3-Bromo-5-[4-ethyl-6-(ethyl-methyl-amino)-pyridin-3-yl]-6-methyl-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

N2-(1-Ethyl-propyl)-5-(2-methoxy-4-trifluoromethoxy-phenyl)-6,N3-dimethyl-pyrazine-2,3-diamine;

[3-Ethyl-5-(6-isopropyl-2-methylamino-pyridin-3-yl)-6-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

3-{3-[6-Ethyl-5-(1-ethyl-propylamino)-3-methoxy-pyrazin-2-yl]-6-isopropyl-pyridin-2-ylamino}-propan-1-ol;

Allyl-{3-bromo-5-[4-ethyl-6-(ethyl-methyl-amino)-pyridin-3-yl]-6-methyl-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

6-Ethyl-5-[6-ethyl-5-(1-ethyl-propylamino)-3-methyl-pyrazin-2-yl]-2-isopropyl-2H-pyridin-1-ol;

N-{3-[5-(1-Ethyl-propylamino)-6-methoxy-3-methyl-pyrazin-2-yl]-6-isopropyl-pyridin-2-yl}-N',N'-dimethyl-propane-1,3-diamine;

1-[3-(1-Ethyl-propylamino)-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyrazin-2-yl]-ethanone;

1-[3-(1-Ethyl-propylamino)-6-(2-methoxy-4-trifluoromethoxy-phenyl)-5-methyl-pyrazin-2-yl]-citanol;

[5-(6-Dimethylamino-4-trifluoromethyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(4-Chloro-6-isopropyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[6-Ethyl-5-(2-ethyl-6-isopropyl-pyridin-3-yl)-3-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[3-Bromo-5-(6-isopropyl-2-methoxy-pyridin-3-yl)-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[6-Ethyl-5-(6-isopropyl-2-methylamino-pyridin-3-yl)-3-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

3-[3-[3-Ethyl-5-(1-ethyl-propylamino)-6-methoxy-pyrazin-2-yl]-6-isopropyl-pyridin-2-ylamino}-propan-1-ol;

{6-Ethyl-5-[6-isopropyl-2-(3-morpholin-4-yl-propylamino)-pyridin-3-yl]-3-methoxy-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

[5-(4-Ethyl-6-isopropyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(2-Ethyl-6-isopropoxy-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[6-Ethyl-5-(6-isopropyl-2-methyl-pyridin-3-yl)-3-methoxy-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

(1-Ethyl-propyl)-[5-(6-isopropyl-2-methyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-amine;

(1-Ethyl-butyl)-[5-(2-ethyl-6-isopropyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-amine;

{6-Ethyl-5-[4-ethyl-6-(ethyl-methyl-amino)-pyridin-3-yl]-3-methoxy-pyrazin-2-yl}-(1-ethyl-propyl)-amine;

(1-Ethyl-butyl)-[5-(6-isopropyl-2-methylamino-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-amine;

[5-(2-Ethylamino-6-isopropyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(2-Dimethylamino-6-isopropyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

(1-Ethyl-butyl)-{5-[6-isopropyl-2-(3-morpholin-4-yl-propylamino)-pyridin-3-yl]-3-methoxy-6-methyl-pyrazin-2-yl}-amine;

[5-(4-Ethyl-6-isopropoxy-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(6-Ethoxy-4-ethyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

[5-(5-Ethyl-6-methoxy-2-methyl-pyridin-3-yl)-3-methoxy-6-methyl-pyrazin-2-yl]-(1-ethyl-propyl)-amine;

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

N-5,N-5'-Bis-(1-ethyl-propyl)- 6,6'-dimethoxy-3,3'-dimethyl-[2,2']bipyrazinyl-5,5'-diamine;

[5-Methyl-6-(5-ethyl-6-methoxy-2-methyl-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-6-(5-ethyl-6-methoxy-2-methyl-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[6-(3,5-Dimethyl-isoxazol-4-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-6-(2-ethyl-6-isopropoxy-2-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-6-(2-ethoxy-6-isopropoxy-2-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-6-(2-methyl-6-isopropyl-2-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-6-(2-hydroxy-6-isopropyl-2-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-6-(2-methyl-6-dimethylamino-2-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[5-Ethyl-6-(2-dimethylamino-6-isopropyl-2-pyridin-3-yl)-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[6-(2-methyl-6-isopropyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[6-(2-Azctidin-1-yl-6-isopropyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[6-(2-Diethylamino-6-isopropyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine;

[3-(1-Ethyl-propoxy)-6-(6-isopropylamino-2-methyl-5-bromo-pyridin-3-yl)-5-bromo-pyrazin-2-yl]-methyl-amine;

[6-(6-Dimethylamino-5-ethyl-2-methyl-pyridin-3-yl)-5-ethyl-3-(1-ethyl-propoxy)-pyrazin-2-yl]-methyl-amine; and

Application No. 10/645,312
Amendment dated October 4, 2005
Reply to Office Action of July 6, 2005

Docket No.: 58288(72021)

[3-(1-Ethyl-propoxy)-6-(6-isopropylamino-2,5-dimethyl-pyridin-3-yl)-5-methyl-pyrazin-2-yl]-methyl-aminc.